orantinib has been researched along with Experimental Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chowbay, B; Lye, KY; Moore, S; Olivo, M; Sharma, A; Zhou, Q | 1 |
| Jiang, XT; Tao, HQ; Zou, SC | 1 |
| Boschi, F; D'Onofrio, M; Faccioli, N; Marzola, P; Pozzi Mucelli, R; Sbarbati, A | 1 |
| Blake, RA; Fong, TA; Hawtin, R; Hirth, KP; Hubbard, SR; Laird, AD; Liang, C; McMahon, G; Mohammadi, M; Schlessinger, J; Shawver, LK; Shenoy, N; Strawn, LM; Sun, L; Tang, C; Tang, F; Thurnher, A; Ullrich, A; Vajkoczy, P | 1 |
| Carver, J; Cherrington, JM; Christensen, JG; Laird, AD; Li, G; Louie, SG; Mendel, DB; Moss, KG; Smith, K; Xin, X | 1 |
1 trial(s) available for orantinib and Experimental Neoplasms
| Article | Year |
|---|---|
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Gene Expression; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Oxindoles; Perylene; Photochemotherapy; Propionates; Protein-Tyrosine Kinases; Proteins; Pyrroles; Survival Rate | 2005 |
4 other study(ies) available for orantinib and Experimental Neoplasms
| Article | Year |
|---|---|
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; Fluorouracil; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Stomach Neoplasms | 2006 |
Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging.
Topics: Adenocarcinoma; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; Indoles; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Microcirculation; Neoplasms, Experimental; Organometallic Compounds; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Rats; Tamoxifen | 2007 |
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Crystallography, X-Ray; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Indoles; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Blood Vessels; Cell Division; Dose-Response Relationship, Drug; Humans; Indoles; Kinetics; Mice; Mice, Nude; Neoplasms, Experimental; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |